Acta Neurochirurgica

, Volume 148, Issue 3, pp 269–275 | Cite as

Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

  • M. Westphal
  • Z. Ram
  • V. Riddle
  • D. Hilt
  • E. Bortey
  • On behalf of the Executive Committee of the Gliadel® Study Group
Clinical Article


Objective. Adjuvant systemic chemotherapy increases survival of primary malignant glioma patients beyond 12–18 months. The only interstitial chemotherapy treatment approved for malignant glioma is Gliadel® wafer containing carmustine (BCNU) placed in the resection cavity at surgery. Analysis of a large trial by Westphal and colleagues (n = 240) showed a 29% risk reduction (P = 0.03) in the BCNU wafer-treated group over the course of the 30-month trial. Long-term follow-up of these patients was undertaken to determine the survival benefit at 2 and 3 years.

Methods. Survival proportions for the placebo and treatment groups over the 56-month study were estimated by the Kaplan-Meier method. Multiple-regression analyses using the Cox proportional hazards model included prognostic factors of age, KPS, and tumor type. A secondary analysis was conducted for 207 GBM patients.

Results. Of the 59 patients available for long-term follow-up, 11 were alive at 56 months: 9 had received BCNU wafers and 2 had received placebo wafers. Median survival of patients treated with BCNU wafers was 13.8 months vs 11.6 months in placebo-treated patients (P = 0.017) with a hazard ratio of 0.73 (P = 0.018), representing a 27% significant risk reduction. This survival advantage was maintained at 1, 2, and 3 years and was statistically significant (P = 0.01) at 3 years. Two of 207 GBM patients remained alive at the end of the follow-up period, both in the BCNU wafer-treated group.

Conclusion. Malignant glioma patients treated with BCNU wafers at the time of initial surgery in combination with radiation therapy demonstrated a survival advantage at 2 and 3 years follow-up compared with placebo.

Keywords: BCNU; brain neoplasms; carmustine; chemotherapy; glioblastoma multiforme; Kaplan-Meier; malignant glioma; neurosurgery; survival analysis. 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brem, H, Piantadosi, S, Burger, PC, Walker, M, Selker, R, Vick, NA, Black, K, Sisti, M, Brem, S, Mohr, G 1995Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.Lancet34510081012CrossRefPubMedGoogle Scholar
  2. CBTRUS (2004) Statistical Report: Primary Brain Tumors in the United States, 1997–2001. Published by the Central Brain Tumor Registry of the United StatesGoogle Scholar
  3. Ekman, M, Westphal, M 2005Cost of brain tumour in Europe.Eur J Neurol124549PubMedGoogle Scholar
  4. Fine, HA, Dear, KB, Loeffler, JS, Black, PM, Canellos, GP 1993Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.Cancer7125852597PubMedGoogle Scholar
  5. Gutin, PH, Prados, MD, Phillips, TL, Wara, WM, Larson, DA, Leibel, SA, Sneed, PK, Levin, VA, Weaver, KA, Silver, P 1991External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2.Int J Radiat Oncol Biol Phys21601606PubMedGoogle Scholar
  6. Leibel, SA, Gutin, PH, Wara, WM, Silver, PS, Larson, DA, Edwards, MS, Lamb, SA, Ham, B, Weaver, KA, Barnett, C 1989Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas.Int J Radiat Oncol Biol Phys1711291139PubMedGoogle Scholar
  7. Meldorf MG, Riddle VD, Gliadel Multicenter Trial Group, Agarwal S (2003) Long-term efficacy of local chemotherapy with biodegradable carmustine implants (Gliadel) in high-grade malignant gliomas. Paper presented at: American Association of Neurological Surgeons (AASN) 2003 Annual Meeting Scientific Program; April 26, 2003; San Diego, CAGoogle Scholar
  8. Stewart, LA 2002Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.Lancet35910111018PubMedGoogle Scholar
  9. Valtonen, S, Timonen, U, Toivanen, P, Kalimo, H, Kivipelto, L, Heiskanen, O, Unsgaard, G, Kuurne, T 1997Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.Neurosurgery414448CrossRefPubMedGoogle Scholar
  10. Westphal, M, Hilt, DC, Bortey, E, Delavault, P, Olivares, R, Warnke, PC, Whittle, IR, Jaaskelainen, J, Ram, Z 2003A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.Neuro-oncol57988CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2006

Authors and Affiliations

  • M. Westphal
    • 1
  • Z. Ram
    • 2
  • V. Riddle
    • 3
  • D. Hilt
    • 4
  • E. Bortey
    • 5
  • On behalf of the Executive Committee of the Gliadel® Study Group
  1. 1.Department of NeurosurgeryUniversity Hospital EppendorfHamburgGermany
  2. 2.Department of NeurosurgeryTel Aviv Sourasky Medical CenterTel AvivTurkey
  3. 3.Pharm Athene, Inc.MarylandUSA
  4. 4.Ascend TherapeuticsUSA
  5. 5.Athero Genics, Inc.GeorgiaUSA

Personalised recommendations